Recent Updates
Recently added Catalysts
PODD Positive Sentiment Score: 75/100

Insulet to Participate in BofA Securities 2026 Health Care Conference

Key Takeaway: Insulet Corporation announced its participation in the BofA Securities 2026 Health Care Conference, scheduled for May 13, 2026. The presentation will showcase Insulet's advancements in insulin delivery technology, particularly the Omnipod product line. The event will be accessible via a live webcast on the company's Investor Relations website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Insulet is recognized as a leader in insulin pump technology.
  • The Omnipod product platform offers innovative solutions for diabetes management.
  • Participation in a major conference highlights Insulet's commitment to healthcare.

Full Press Release Details

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader intubeless insulin pump technologywith its Omnipod® brand of products, today announced that management will present at the BofA Securities 2026 Health Care Conference in Las Vegas on Wednesday, May 13, 2026 at 9:20 a.m. (Pacific Time).
The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website:investors.insulet.com/events.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visitinsulet.comandomnipod.com.
©2026 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved.

Frequently Asked Questions

When will Insulet present at the BofA Securities Conference?

Insulet will present on May 13, 2026, at 9:20 a.m. Pacific Time.

Where can I watch Insulet's presentation?

The presentation will be available via a live webcast on Insulet's Investor Relations website.

What is the Omnipod product platform?

The Omnipod platform offers a tubeless insulin delivery system designed for diabetes management.

What is the significance of the BofA Securities Conference?

The conference provides a platform for Insulet to showcase its innovations in healthcare.

Last updated: Apr 28, 2026